收藏切换
Cost effectiveness analysis of blinatumomab in pediatric patients with relapsed or refractory precursor B-Cell acute lymphoblastic leukemia in China
收藏切换
Weiqi CHEN1, Qiyun ZHU2, Qinyi SUN2, Zhao YANG2, 3, Bin JIANG1, 2, *
World Clinical Drug | 2024, 45(1) : 45 - 52
Less
收藏切换
World Clinical Drug | 2024, 45(1): 45-52
• Article •
Cost effectiveness analysis of blinatumomab in pediatric patients with relapsed or refractory precursor B-Cell acute lymphoblastic leukemia in China
Full
Weiqi CHEN1, Qiyun ZHU2, Qinyi SUN2, Zhao YANG2, 3, Bin JIANG1, 2, *
Affiliations
  • 1.School of Pharmacy, Peking University, Beijing 100191, China
  • 2.Public Policy Research Center, Peking University, Beijing 100871, China
  • 3.Scientific Research Department, Peking University First Hospital, Beijing 100034, China
Published: 2024-01-10 doi: 10.13683/j.wph.2024.01.008
Outline
收藏切换
Objective

To compare the cost effectiveness of blinatumomab and chemotherapy in the treatment of relapsed or refractory precursor B-Cell acute lymphoblastic leukemia (ALL) from Chinese societal perspective.

Methods

A partition survival model with three health states (event-free, recurrence and death) was conducted over a 20 years horizon. Clinical data accessed from the phase Ⅲ randomized controlled clinical study 20120215, utility values were obtained from the quality of life study of leukemia patients in Shanghai Children's Medical Centre, and cost inputs were identified from the Eliancloud database, Menet database, National Bureau of Statistics etc. The threshold of willingness to pay (WTP) was CNY 128 547 (1.50 times of 2022 Chinese per capita GDP). Deterministic sensitivity analysis and probabilistic sensitivity analysis were conducted to access the robustness of model and findings.

Results

The patients of intervention group achieved 8.74 quality-adjusted life years (QALYs) and 10.53 life years (LYs), compared with control group, an increase of 3.01 QALYs and 3.46 LYs. The total cost for intervention group was CNY 1 060 929, an increase of CNY 245 719 compared with control group. The incremental cost effectiveness ratio (ICER) in intervention group compared with control group was CNY 81 623 per QALY. Results were robust to sensitivity analyses.

Conclusion

Blinatumomab is more cost effective in pediatric patients with relapsed or refractory precursor B-Cell ALL compared with chemotherapy from Chinese societal perspective.

acute lymphoblastic leukemia  /  blinatumomab  /  chemotherapy  /  partitioned survival model  /  cost-effectiveness analysis
陈伟琪, 朱奇云, 孙沁怡, 杨照, 江滨. 注射用贝林妥欧单抗治疗中国儿童复发或难治性急性淋巴细胞白血病的成本-效果分析. 世界临床药物, 2024 , 45 (1) : 45 -52 . DOI: 10.13683/j.wph.2024.01.008
Weiqi CHEN, Qiyun ZHU, Qinyi SUN, Zhao YANG, Bin JIANG. Cost effectiveness analysis of blinatumomab in pediatric patients with relapsed or refractory precursor B-Cell acute lymphoblastic leukemia in China[J]. World Clinical Drug, 2024 , 45 (1) : 45 -52 . DOI: 10.13683/j.wph.2024.01.008
Year 2024 volume 45 Issue 1
21
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.01.008
  • Receive Date:2023-10-31
  • Online Date:2026-11-18
  • Published:2024-01-10
Article Data
Affiliations
History
  • Received:2023-10-31
Affiliations
    1.School of Pharmacy, Peking University, Beijing 100191, China
    2.Public Policy Research Center, Peking University, Beijing 100871, China
    3.Scientific Research Department, Peking University First Hospital, Beijing 100034, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.01.008
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT